Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 4/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6967657 | 0.79 | PGR (0.57) | PGRMAPK8MAPK9SMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL7124568 | 0.78 | PGR (0.56) | PGRMAPK8MAPK9SMN1; SMN2POLB | |
| SCHEMBL6978729 | 0.78 | PGR (0.59) | PGRMAPK8MAPK9SMN1; SMN2ADORA2B | |
| SCHEMBL6975699 | 0.76 | PGR (0.59) | PGRMAPK8MAPK9SMN1; SMN2POLB | |
| SCHEMBL7651124 | 0.74 | PGR (0.68) | PGRMAPK8MAPK9SMN1; SMN2POLB | |
| SCHEMBL6980952 | 0.74 | PGR (0.59) | PGRMAPK8MAPK9MAPTTP53 | |
| SCHEMBL7119803 | 0.74 | PGR (0.51) | PGRMAPK8MAPK9SMN1; SMN2POLB | |
| SCHEMBL6977516 | 0.73 | PGR (0.58) | PGRSMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL6979751 | 0.72 | PGR (0.58) | PGRMAPK8MAPK9SMN1; SMN2POLB | |
| SCHEMBL6977985 | 0.72 | PGR (0.59) | PGRMAPK8MAPK9POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | PGR 4288/4885MAPK8 2430/4885MAPK9 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.